hyperparathyroidism and harbored the same mutations as that found in families with authentic MEN1. An association existed between large rearrangements and an earlier onset of the disease, whereas no difference was observed between truncating and nontruncating variants.
Conclusion:
The UMD-MEN1 database provides an exhaustive overview of the MEN1 variants present in the French population. For each variant, a classification is publicly available. Clinical data collections allow the determination of genotype-phenotype correlation and age-related penetrance of lesions in the cohort. (J Clin Endocrinol Metab 104: [753] [754] [755] [756] [757] [758] [759] [760] [761] [762] [763] [764] 2019) M ultiple endocrine neoplasia type 1 (MEN1) is an inherited disease that predisposes carriers to primary hyperparathyroidism (HPTH), duodenopancreatic neuroendocrine tumors (DP-NETs), pituitary adenomas (PITs), adrenal tumors (ADREs), and thymic or bronchial neuroendocrine tumors (1) . MEN1 is caused by a heterozygous mutation in MEN1, a tumor suppressor gene located in chromosome 11q13 (2, 3) . MEN1 encodes menin, a 610 amino acid protein expressed in numerous tissues (4, 5) . Menin is a nuclear protein with several molecular functions, such as chromatin, protein, and DNA binding. This protein is also involved in many biological processes, such as negative regulation of the cell cycle, DNA repair, cytoskeletal components, regulation of transcription (menin inhibits the transcriptional activation by JunD), and regulation of telomerase activity (4) (5) (6) (7) .
MEN1 disease may display various clinical associations; the criteria for diagnosis were first established in Gubbio, Italy, and then regularly updated (8) (9) (10) . MEN1 disease is usually described as an autosomal-dominant tumoral syndrome that is very progressive with a high penetrance during the lifespan (9, 11, 12) . The clinical expression of the disease is variable, depending on the type of developed tumors. HPTH is present in 90% to 95% of cases (8, 10, (13) (14) (15) . DP-NETs occur in 30% to 70% of patients with MEN1, and the third major manifestation, PIT, is reported in 30% to 40% of patients with MEN1 (10) . The penetrance for all clinical features increases to 95% at age 40 years (10, 16) An increased risk for breast cancer has also been described in women with MEN1 mutations (17) .
In 2012, a group of experts, including physicians, surgeons, and geneticists from international centers, provided guidelines for the evaluation and treatment of and genetic testing for the MEN1 gene (10) . They redefined the bases for MEN1 diagnosis according to three categories of criteria: (i) clinical criterion: a patient with two or more MEN1-associated endocrine tumors (i.e., HPTH, DP-NET, or PIT); (ii) familial criterion: a patient with one MEN1-associated tumor and a first-degree relative with MEN1; and (iii) genetic criterion: an individual who has a MEN1 mutation but does not have clinical or biochemical manifestations of MEN1 (i.e., a mutant gene carrier) (10).
The group proposed three different situations in which the MEN1 mutational analysis should be undertaken (10) : (i) in index cases with clinical MEN1; (ii) in index cases with suspected or atypical MEN1, which includes patients with HPTH before the age of 30 years, patients with multigland or multiple diseases in the same gland at any age (e.g., multigland parathyroid disease), or patients harboring two or more MEN1-associated tumors, including one other than HPTH, PIT, and DP-NET (e.g., HPTH plus ADRE); and (iii) in first-degree relatives of known MEN1 mutation carriers, whether asymptomatic or not.
Since the beginning of genetic testing, and owing to early and suitable therapies, the discovery of a causal variant in the MEN1 gene has reduced the morbidity of patients with MEN1 (8, 10, 18, 19) . The MEN1 gene presents a broad spectrum of variants, including large deletions, and truncating, missense, or splicing point mutations (20) . No mutational hot spot has been defined, but some recurrent mutations have been described (20) (21) (22) (23) . The genotype-phenotype relationship remains under debate. In some kindred, only HPTH appears to develop in MEN1 variants carriers; this situation of MEN1-mutation-related disease is referred as familial isolated hyperparathyroidism (FIHP), a rare, heritable disorder, characterized by hypercalcemia, inappropriately high PTH levels, and isolated parathyroid tumors with no evidence of hyperfunction of any other endocrine tissues (24, 25) . FIHP seems to be more associated with MEN1 missense variants (20) . The age-dependent penetrance and the variability of intra-and interfamilial expression of the disease increase the difficulty of interpretation of allelic variants in the MEN1 gene, particularly regarding sporadic patients with incomplete diagnosis criteria (22) . In this context, the discovery of nontruncating MEN1 variants may be a challenge for interpretation.
Here, we present the French Universal Mutation Database (UMD) for the MEN1 gene (UMD-MEN1) developed with the UMD-Software. This project, funded by the Institut National de lutte contre le Cancer (INCa) and the French Ministry of Health, was initiated by a French national consortium and received the effective participation of the four French laboratories performing a comprehensive MEN1 molecular analysis.
The UMD-MEN1 database is a locus-specific database designed to provide centralized and updated sequencing data for MEN1 and interactive tools for the interpretation of sequencing variants in an attempt to classify the new variants (NVs) in one of the five classes of pathogenicity in accordance with international recommendations (26) .
Materials and Methods

Organization of the MEN1 gene analysis in France
To facilitate access to health care, the French Ministry of Health, via INCa, organized the genetic screening of French patients by funding regional platforms of molecular biology. Four laboratories belonging to the French Oncogenetics Network of Neuroendocrine Tumors (TENGEN) performed, until 2015, the totality of the MEN1 gene testing, according to the international recommendations (10, 27) . In France, MEN1 genetic testing is performed in patients with clinical MEN1 or suspected MEN1, including patients in whom isolated HPTH has developed before the age of 50 years, isolated PIT before the age of 30 years, isolated DP-NET, regardless of age, isolated bronchial or thymic carcinoid tumor, regardless of age.
Laboratory practices for MEN1 gene molecular analysis
The genetic analyses were performed after written informed consent was given by the patients during a one-on-one genetic counseling session. The sequencing of the full coding sequences and exon-intron junctions (210 to +10 nucleotides from the splicing sites) of the MEN1 gene were performed in all index cases. Genetic analyses were achieved using Sanger sequencing or targeted next-generation sequencing from blood leukocyte DNA. In case of negative sequencing screening, large rearrangements (RGTs; i.e., a deletions or duplications of at least one MEN1 exon) were screened by quantitative multiplex PCR of short fluorescent fragments or multiplex ligationdependent probe amplification (MLPA; MRC-Holland, Amsterdam, Netherlands).
The screening of relatives was based on the targeted research for the familial variants. Genotypes were double-checked on two independent biological samples.
UMD-MEN1 database: data collection and implementation for MEN1 variants
Project and online publishing was approved by the French supervisory authority, Commission Nationale pour l'Informatique et les Libertés (registration no. 908361) and the national ethics committee, Comité Consultatif pour le Traitement de l'Information en matière de Recherche dans le domaine de la Santé (no. 07.421), and registered under no. 91513.
An anonymized number was created for each patient and a second number was generated for each family. Genetic and phenotypic data were collected for patients with a MEN1 variant. Patients (index cases or relatives) with negative MEN1 genetic testing or patients who only had MEN1 polymorphisms were not included in the database.
Clinical description
The laboratories in charge of the analysis collected clinical data from all patients harboring a MEN1 variant. Clinical data included the date of birth, the MEN1-related clinical manifestation, the age at which the patient experienced manifestations of MEN1 disease, and the presence of a family history of MEN1 spectrum disorders. Cosegregation data were collected when available.
Molecular data
All variants were annotated using the same reference transcript (NM_130799) in the human genome GRCh37. They were named according to the Human Genome Variation Society nomenclature before implementation in the process (28) . For all variants, the molecular data included the variant and the notion of variant co-occurrence. In silico predictions, including conservation level, SIFT, Polyphen 2, UMD-Predictor, and splicing consequence estimates, were collected.
Variant classification
Each variant was classified using a process consistent with the guidelines of the American College of Medical Genetics and Genomics in one of the following five classes (26) Because of the many examples in the literature of pathogenic midintronic or synonymous variants, these types of variants were not excluded from the analysis and were classified using the same method used for missense variants and microrearrangements (microRGTs) (29) .
Systematic literature and database reviews were performed. Four additional pieces of information were also collected according to the case-by-case relevance: (i) screening of parents and relatives: to determine the de novo nature of the variant or to assess the variant cosegregation in multiple affected members; (ii) clinical phenotype and age of onset; (iii) additional molecular testing, including the sequencing of genes involved in phenocopies (i.e., AIP, HRPT2, CaSR, and CDKN1B), screening of large RGTs by MLPA (the MEN1 MLPA kits also explored AIP or CDKN1B) (18); and (iv) functional analysis: splicing analysis by direct RNA sequencing, search for a loss of heterozygosity in tumors, and in vitro testing of the mutation (stability and splicing).
Each NV with the all the related data was submitted to a consensus interpretation by the TENGEN expert group during a biannual meeting to classify it and the NV then was included in the UMD-MEN1 database.
Database description
Search tools
Database query is possible by the exon number, by the type of mutation, or directly by the amino acid or nucleotide position.
Interpretation tools
For each position and variant, all cases were listed and linked to the literature references. In silico predictions, conservation level, SIFT, and UMD-Predictor estimates were directly integrated into the UMD database structure. They were automatically activated when the "summary" of the corresponding variation was opened. A table and graphical view of splicing analyses from Human Splicing Finder is available for each intronic variant (30) .
Statistical analysis
Statistical analyses were performed using Prism, version 6.0 (GraphPad Software, La Jolla, CA). Patients' characteristics were compared using the two-tailed Fisher exact test for qualitative variables. The age-related penetrance of the MEN1-related lesions and the first MEN1 manifestation were estimated using the Kaplan-Meier method and analyzed with the log-rank test (aka, Mantel-Cox test). Statistical significance was set at P , 0.05.
Results
Characterization of the MEN1-positive patients reported in the UMD-MEN1 database
From 1997 to 2015, 5754 index cases in France and 2065 relatives of index cases positive for MEN1mutation were screened for MEN1 gene mutations (INCa database). Over that period, the laboratories declared to the health authorities that MEN1 genetic testing was positive in 721 index cases (12.5%). The cooperative effort made by the TENGEN group has led to the recovery of the molecular data of 680 index cases testing positive for MEN1 that were referred in the UMD-MEN1 database, underlining the completeness of MEN1 data collection in the French population. As expected in an autosomaldominant disorder, the genetic testing was positive in half of MEN1-screened relatives (n = 996 MEN1-positive relatives for 2065 screened relatives; 48.2%).
Clinical data were available for 95.7% of MEN1-positive patients referred in the database (1604 of 1676; Table 1 ). One-third of the MEN1-positive relatives were asymptomatic. The mean age at last follow-up of asymptomatic relatives was 28 years (range, 0 to 88 years). The age-related penetrance of the MEN1 manifestations was consistent with the previous published data (Fig. 1) (8-16) . As expected, HPTH was the most common lesion in all patients (79.9% of index cases and 57.6% of MEN1-positive relatives). FIHP represented 1.9% of families (including eight index cases and 10 relatives).
Characterization of the variants in the MEN1 gene reported in the UMD-MEN1 database
Altogether, 370 different variants from the 1676 entries were included in the UMD-MEN1 database (Fig. 2) . To our knowledge, more than half of the MEN1 variants in the database have not been reported before in the literature (n = 181 of 370; Supplemental Table 2 ).
Point variations
Nucleotide substitutions (i.e., nonsense, missense, splice junction, midintronic, and synonymous variants) represented 64.9% of all MEN1 variants (n = 240 of 370; Fig. 2 ). Missense variants were the most frequent type (33% of mutations; n = 122 of 370). Overall, 122 missense variants were registered and represented 26.2% of the index cases.
Microrearrangements
Microrearrangements [i.e., deletions, insertions, duplications, insertions and deletions (indels) of one or few bases] represented one-third of the mutational events in the MEN1 gene (n = 122 of 370 variants) and were present in 46.2% of the index cases. Most (88.5%) microRGTs led to a frameshift in the coding sequence inducing a premature codon stop and were, consequently, truncating mutations.
Large RGTs
A large RGT is a rare event. Eight distinct, large MEN1 deletions were identified, ranging from one exon Pathogenicity of the MEN1 variants Seven MEN1 BVs were reported in the UMD-MEN1 database: two in the introns and five in the coding sequence (Table 2) (32). All previously were reported as polymorphisms.
Of the variants referenced in the UMD MEN1 database, 73% were pathogenic variants (PVs) or LPVs (Fig. 3) . Despite the classification process, 16.2% were VUSs; LBVs or BVs represented 10.8% of the MEN1 variants, and they were principally midintronic, synonymous, or missense variants.
LPVs or PVs represented 60.9% of the MEN1 missense variants. One-third of the missense MEN1 variants were VUSs, mainly owing to the lack of clinical and segregation data. LBVs and BVs were uncommon in the MEN1 gene, including the missense variants.
Co-occurring variants
Excluding BVs, five co-occurring variants were reported in the UMD-MEN1 database ( Table 3) . The occurrence of a VUS with LPV or PV was used to reclassify the VUS as an LBV according to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology guidelines (26) .
Analysis of the MEN1 mutations spectrum in the French population
Molecular data collection confirmed a large mutational spectrum from MEN1-positive patients (Table 4) . Frameshift microRGTs (i.e., microdeletions, microduplications, microinsertions, indels with frameshift consequence) represented the most frequent type of MEN1 variants identified in the index cases (43.8%); the second most frequent type was missense variants (26.2%).
Excluding BVs, most variants were identified in only one index case (74%; n = 269 of 363) or two index cases (13%; n = 47 of 363), underlining the occurrence of MEN1 private mutations in MEN1 patients. Only 47 variants were identified in three or more index cases (13%); among them, only six variants were recurrent MEN1 PVs with a frequency .1.5% in the index cases referenced in the UMD-MEN1 database (Table 5 ). 
Variants associated with FIHP
The UMD-MEN1 database revealed eight families with FIHP (Table 6 ). Variants involved in FIHP were frameshift microRGTs or nonsense variants in two families and variants affecting splicing in three families. Missense variants were reported in only one FIHP family. Splicing variants were then overrepresented in French FIHP families compared with the MEN1 families [OR, 5.49 (95% CI, 1.283 to 23.49); Fisher exact test P = 0.04)].
Location of the MEN1 variation events across menin
Even if the variants were localized throughout the gene, 65.1% of the causal or likely causal MEN1 variants identified in the French population were located in exons 2 and 10, including four of six of the most frequent variants of MEN1 ( Fig. 4 ; Table 5 ). Exon 10 harbors the two most frequently mutated nucleotides: position 1546 is the seat of frameshift microRGTs (31 deletions and 8 duplications) in 39 index cases (5.8%), and position 1378 showed a nonsense change in 18 index cases and a frameshift microRGT in 5 index cases. The LBVs involving the coding sequence also more frequently occurred in exon 10 (n = 13 of 29).
Genotype and phenotype correlations
We compared the age of onset of MEN1-related lesions in three populations of patients: those with large RGTs, those with truncating variants, and those with nontruncating variants. Variants affecting splice junction, synonymous or midintronic variants, or variants causing start-codon loss were not included in the analysis, because of the lack of systematic cDNA sequencing, to determine if they caused a premature stop codon. Index cases and relatives harboring MEN1 variants of unknown significance or benign, or likely benign, variants were also not considered in this analysis. The three populations were similar in terms of age at last follow-up and age at molecular diagnosis (Supplemental Fig. 1 ) for index cases and relatives.
All patients with MEN1 with large MEN1 RGTs had earlier onset of lesions than did patients with MEN1 with nontruncating or truncating variants (Fig. 5) . HPTH and PITs manifested earlier in patients harboring large MEN1 RGTs than in patients with nontruncating or truncating variants (Fig. 5 ), but the age at onset of DPNETs was similar. For the patients harboring large MEN1 RGTs, the median ages, reported as years (range), at occurrence of the first lesion, HPTH, PIT, DP-NET, and ADRE were, respectively, 28 (10 to 74), 30 (10 to 74), 22 (14 to 60), 34 (12 to 68), and 43 (21 to 55). The first lesion of MEN1 developed earlier in patients with truncating variants than in patients with nontruncating variants (log-rank test P = 0.012), but the age at onset of each major MEN1-related manifestation was similar. For the patients 
Discussion
Position of the UMD-MEN1 database in public databases and database update UMD-MEN1 is a public, open-access database accessible through the framework of the Human Genome Variation Society (www.hgvs.org or www.umd.be/ MEN1/). With 370 variant entries, the UMD-MEN1 database is the first database collecting the MEN1 variants and proposing molecular interpretation at no charge for all registered variants by an expert group. With 181 unreported MEN1 variants, the UMD-MEN1 database complements the knowledge of the MEN1 mutation spectrum. As with all UMD databases, the UMD-MEN1 database allows interpretation of sequence variants with online interactive in silico tools, such as SIFT, UMD-predictor, or Human Splicing Finder. For registered patients, age at MEN1 onset is the only accessible clinical data.
Database update
Implementations of NVs are performed when they are communicated to the curator. Twice a year, the TEN-GEN group reviews the classification of NVs. The curator updates the literature, molecular data, clinical data, and results of functional analysis. The UMD-MEN1 database is then upgraded.
The UMD-MEN1 database provides an overview of MEN1 variants present in the French population
With data collected from 680 MEN1-positive index cases from 1997 to 2015, the UMD-MEN1 database provides a comprehensive overview of MEN1 variants present in the French population. The relative low frequency of MEN1 variants in the tested index cases is explained by the broad indication for MEN1 genetic screening. Classification of patients according to their status as index cases or relatives enables accurate statistical analysis of variant frequency according to the types of molecular events.
In accordance with previous studies, we found MEN1 variants are distributed all along the gene. Overrepresentation of variants in exons 2 or 10 has been classically attributed to the proportionally larger size of these two exons. Nevertheless, variants in exons 2 or 10 represent 50% of the MEN1 microRGTs and punctual variants, highlighting the requirement to entirely cover the MEN1 coding sequence in high-throughput sequencing strategies. Six recurrent variants were reported in the UMD-MEN1 database with a frequency .1.5% (Table 5 ). The relatively high frequency of five of these six variants has been previously highlighted (20) . We also identified one frequent variant in exon 9 in the French population, c.1252G.A, p.(Asp418Asn), suggesting a founder effect in France. Large RGTs were reported with a frequency of 2.2% in index cases, underlying the need to perform copynumber variation screening by MLPA or next-generation sequencing in cases of patients with MEN1 without variants identified in the MEN1 coding sequence. According to the literature, no mutation could be found in 10% to 30% of patients suspected of having MEN1, despite an extensive analysis of the MEN1 locus (20, 33, 34) .
The UMD-MEN1 database confirmed that the most frequent variant types in index cases with MEN1 genetic testing were frameshift microRGTs (43.8%) and missense variants (26.2%) (20) . Interpretation of missense variants may be difficult, in particular in sporadic presentation with incomplete phenotype. The implemented process for interpretation allowed classification of 68% of the missense variants as (likely) benign or (likely) pathogenic. Missense variants reported as PVs or LPVs represented 61.5% of the missense variants, against 6.6% for the BV or LBVs. The low number of BVs or LBVs is in agreement with the low number of known polymorphisms identified in the MEN1 gene (i.e., four in the coding region) (35) . Missense BVs or LBVs are frequently identified in exon 10. For these variants, in silico three-dimensional modeling was not contributive, because of a probable moving loop in the protein structure (PyMOL), supporting the evidence of a benign effect (36) . The remaining 32% of variants were classified as VUS, awaiting supplemental data from cosegregation studies or functional studies.
Genotype-phenotype correlations
The clinical data in the UMD-MEN1 database allowed us to establish age-related penetrance of the first MEN1 manifestations and age-related penetrance of HPTH, PIT, DP-NET, and ADRE. Because of the large number of families and the various types of mutant events, the UMD-MEN1 database cohort was relevant and accurate for the description of the MEN1-positive patients' outcome.
The UMD-MEN1 database revealed a phenotype difference between patients harboring large RGTs and those with truncating or nontruncating variants. All considered patients with MEN1 with large RGTs (37) . In more than half of patients (those most recently tested), MLPA did not found an AIP deletion associated with MEN1 deletion. Overall, these data support earlier molecular screening in families with large RGTs. FIHP was a rare event in families in the UMD-MEN1 database (18 MEN1-positive patients in 8 of 416 families; 1.9%). FIHP was not preferentially associated with missense variants in our series, in contrast to the findings of others (20, 24) . Each of the variants identified in FIHP was also reported in at least one MEN1-positive index case in the database harboring the other major MEN1-related lesions, except for the variants of the families F6 and F7 (Table 5 ). Both F6 and F7 variants affected splicing and were reported in the literature on patients with MEN1 (38, 39) . In the first case, phenotypic description of the patient was not available; in the second case, the patient was reported as harboring HPTH, PIT, and DP-NET. In the F6 and F7 families, four of five patients were younger than 50 years and were still subject to development of secondary MEN1-related lesions. These data did not allow for adapting the clinical treatment of the MEN1-positive patients in the FIHP families to be different than the treatment in MEN1 families.
The UMD-MEN1 database can improve the genetic counseling and medical care of families of patients with MEN1
The identification of the MEN1 gene in 1997 modified the landscape of MEN1 disease in MEN1 families by providing a predictive test for the risk of MEN1 lesions developing in relatives (2) . Today, because of the discovery of VUS, MEN1 genetic testing remains challenging in patients and families in which genetic analysis was uninformative. For example, in the MEN1 ClinVar dataset, 37.2% of the MEN1 variants are VUS (n = 256 of 688); this proportion increases to 80.6% in the category of missense variants (n = 187 of 232). In the UMD-MEN1 database, the collaborative work among laboratories, geneticists, and physicians led only 60 of all 370 variants (16.2%) and only 39 of 122 as missense variants (32%), to be qualified as VUS (Fig. 3) . Theoretically, VUS is a transitional classification state. VUSs should not be used in medical decisions for the patient or relatives. Concerted efforts between geneticists and physicians have to be undertaken to resolve the VUS classification, incorporating a detailed phenotypic description. Testing additional family members for segregation analysis or functional analysis could result in the classification of these variants, but this is not always practicable. Extensive segregation studies are often difficult to perform, owing to the lack of compliance of patients and their relatives, the time required for the physicians and laboratories, and the expense. The interpretation of segregation studies may be difficult, because of the age-dependent penetrance and expressivity of the disease. The accumulation of data from several families harboring the same variants should compensate for lack of intrafamilial data. That is why sharing data on genes, variants, and phenotypes, through databases, is key to offering optimal care to patients and their families.
In conclusion, the UMD-MEN1 database is a locusspecific database designed to provide centralized and updated sequencing data for MEN1 and interactive tools for the interpretation of sequence variants. Thanks to a publicly funded national collaborative network (the TENGEN group), the UMD-MEN1 database provides an exhaustive overview of the MEN1 variants present in the French population. Knowledge sharing, standardization efforts, and implementation have contributed to the extensive expertise of the TENGEN group in the classification of MEN1 variants. To date, the database contains data on 370 different variants from 1676 patients, including 181 NVs. The UMD MEN1 database is also open to other laboratories worldwide. For each variant, a classification, resulting from a consensus interpretation based on the clinical data collection from patients and a standardized analysis, is publicly available. The UMD-MEN1 database represents a public knowledge base, allowing access to original data and interactive tools to help geneticists and molecular biologists interpret their sequencing results in patients with MEN1.
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